Product Development Pipeline and Partnering Opportunities

Our first product AIM ACT, uses aAPCs to stimulate multiple antigen-specific, cancer-fighting T cells for the treatment of cancer. The AIM™ technology can also be used for the development or enhancement of other cancer treatments and for use in treating infectious diseases and autoimmune diseases.